Background {#Sec1}
==========

Huntington's Disease (HD) is a hereditary neurodegenerative disorder which results in a number of motor, cognitive, and psychiatric symptoms. The condition is characterised by involuntary movements, known as chorea, and an impairment of voluntary movements. Learning and memory problems, depression, obsessive compulsive disorder, and psychosis are frequently reported, as are personality and behaviour changes including apathy, irritability, impulsivity, and obsessionality \[[@CR1]\].

HD onset usually occurs when individuals are in their forties, there are no therapies currently available that alter the disease course, and people with HD tend to live only 10--20 years from diagnosis. The gene which causes HD is fully penetrant \[[@CR2]\], and it has a devastating effect on an individual's ability to walk, think, talk and reason \[[@CR1]\]. In addition, individuals with HD have a 50% chance of passing the disease onto their children \[[@CR3]\]. Diagnosis can have major implications which affect not only the person with HD, but also the rest of the family who may also be at risk of developing the disease \[[@CR4]\].

The disorder is relatively uncommon. For example, in 2012, a systematic review and meta-analysis estimated that there was an overall prevalence of adults with HD in Europe, North America, and Australia of 5.7 per 100,000 people \[[@CR5]\]. Hence, despite its devastating impact on affected families, HD receives little attention at a national, or international, level. For example, the National Institute for Health and Care Excellence (NICE) \[[@CR6]\], which provides guidelines for resource allocation regarding health and social care in the UK, makes no specific reference to the funding of treatments for people with HD.

The breadth of the personal, social, and economic impact of HD has, to date, been under-explored. Research by Busse et al. \[[@CR7]\], utilising data from the European Huntington's Disease Network (EHDN), has been fundamental to starting to establish the health, social, and economic impacts of HD. This work has estimated the proportions of people with HD who use formal and informal care services, and has explored relationships between resource use, disease severity and functional ability. However, to date, no research is apparent which has reported the health-related quality of life (HRQoL) of people with HD in a manner that can be used in policy-relevant economic evaluations of treatments for the condition.

Health outcomes, in the context of health policy decision-making, are frequently considered in the form of quality-adjusted life-years (QALYs). QALYs combine quantity and quality of life in a single outcome measure, whereby length of life is adjusted by a weight representing the quality of life during that time. These quality weights, which are often referred to as health state utility values (HSUVs), can be estimated from preference-based measures \[[@CR8]\]. Two of the most commonly used preference-based measures internationally are the EQ-5D \[[@CR9]\] and the SF-6D \[[@CR10]\].

We conducted a systematic review of HSUVs for HD. This identified just two relevant studies \[[@CR11]\] \[[@CR12]\]. Research by Hocaoglu et al. \[[@CR11]\] focussed on exploring patient-proxy ratings of HRQoL at different stages of HD and investigated the factors which affect proxy ratings, whilst the study by Calvert et al. \[[@CR12]\] considered the impact of rare long-term neurological conditions, including HD, on people's HRQoL. Both studies were conducted in the UK and included samples of 105 and 53 people with HD, respectively. The EQ-5D was used in both studies and no breakdown was provided by demographic or clinical characteristics or disease staging. As such, very little is documented about HSUVs of people with HD.

Aims {#Sec2}
====

The aims of this research were:

to describe HSUVs for HD by demographic and clinical characteristics, using data from a European longitudinal, observational study;to compare HSUVs of people in the UK with HD with population norms;to identify the relative strength of demographic and clinical characteristics in predicting HSUVs for HD.

Methods {#Sec3}
=======

Participants {#Sec4}
------------

Data from the European Huntington's Disease Network REGISTRY study \[[@CR13]\] were used for analysis. This is a multi-centre, multi-national, observational, longitudinal study of people with HD across Europe. Participants complete a six-monthly battery of demographic, clinical, and patient-reported outcome measures, including gender, age, time since diagnosis, disease severity stage according to the Shoulson--Fahn Functional Capacity Rating Scale \[[@CR14]\] and motor, cognitive, functional, and behavioural symptoms as rated by the United Huntington's Disease Rating Scale (UHDRS) \[[@CR15]\], and the SF-36. Participants enrolled in the REGISTRY study provide informed, written consent for their anonymised data to be used for research purposes. All those who had provided initial data as of October 2014 were included in the following analyses.

Measures {#Sec5}
--------

### United Huntington's Disease Rating Scale (UHDRS) \[[@CR15]\] {#Sec6}

The UHDRS was developed as a clinical rating scale to assess four domains relating to the clinical features of HD and the course of the disease: motor function, cognitive function, behavioural difficulties, and functional capacity. The measure has undergone extensive reliability and validity testing and has been used as a primary outcome measure in a number of controlled clinical trials. The domains are scored separately, as follows.

#### Total Functional Capacity (TFC) {#Sec7}

This rates a person's independence, using Likert scales, in terms of five domains (occupation, ability to manage finances, ability to perform domestic chores, ability to perform personal activities of daily living, and setting for level of care). The score is the sum of Likert responses (0--3, or 0--2) to five items. Scores range from 0 to 13, with higher scores indicating higher functional capacity. A score of 13/13 is possible on the TFC. This corresponds to functional independence of an individual who has been diagnosed with HD, but has no symptoms.

#### Behavioural score {#Sec8}

This is the sum of Likert responses (scored 0--4) which rate the frequency and the severity of 11 behavioural symptoms (e.g., sad/mood, low self-esteem/guilt, disruptive or aggressive behaviour, obsessions, hallucinations, and irritable behaviour). Scores can range from 0 to 88, with higher scores indicative of increased problems.

#### Cognition score {#Sec9}

This is the sum of raw scores (number of correct responses) to five cognitive tests. These are a phonemic verbal fluency test (the Controlled Oral Word Association test \[[@CR16]\], the Symbol Digit Modalities test \[[@CR17]\], and three scores generated from the Stroop Color and Word tests \[[@CR18]\]. Higher scores are indicative of better functioning.

#### Motor score {#Sec10}

This is the sum of Likert responses (scored 0--4) to 31 motor symptoms items, e.g., ocular pursuit, maximal chorea, gait, and tongue protrusion). Scores range from 0 to 124, with higher scores indicating greater impairment.

### Shoulson--Fahn Functional Capacity Rating Scale \[[@CR19]\] {#Sec11}

The TFC score can be used to categorise people into five disease stages defined by the Shoulson--Fahn Functional Capacity Rating Scale. Stage I (earliest stage) includes scores 11--13, Stage II scores 7--10, Stage III scores 3--6, Stage IV scores 1--2, and Stage V score 0 (most advanced stage). Individuals in Stage I may be pre-manifest, i.e., they may have been diagnosed with the condition via genetic testing, but have no clinical expression, Stage II can be characterised by issues with work and some impairment with usual activities, Stage III may include problems with activities of daily living and the requirement for some care support, Stage IV indicates the need for assistance with most activities of daily living and 24 h care may be appropriate, and Stage V is indicative of requiring support with all activities of daily living and progression to the terminal phase of the condition.

### Sf-36/Sf-6d \[[@CR20]\] {#Sec12}

The SF-36 includes 36 self-report questions which assess functional health and well-being from the patient's perspective over the previous 4 weeks \[[@CR20]\]. The measure is one of the most widely used tools worldwide for measuring patient-reported outcomes. Participant responses to the SF-36 were converted to SF-6D values using the algorithm provided by Brazier et al. (2002). The SF-6D \[[@CR10]\] is a preference-based measure of health, which provides health state utility values. Scores on the SF-6D can range from 0.3 to 1.0, where 0.3 indicates the worst health state and 1.0 the best health state.

Data analyses {#Sec13}
-------------

Mean (SD) SF-6D HSUVs were described by gender, age (under 35 years, 35--44 years, 45--54 years, 55--64 years, and 65 years and over), time since diagnosis (1--4 years, 5--9 years, 10 years or more), and disease stage according to the Shoulson--Fahn Functional Capacity Rating Scale (Stage I, Stage II, Stage III, and Stage IV/V). The values were described individually for the 12 European countries and across the countries as a whole. The SF-6D values from people with HD in the UK were compared with SF-6D norms for a representative sample of the UK population, reported by age \[[@CR21]\].

A random-effects linear regression analysis was conducted to estimate the relative strength of age, gender, time since diagnosis, and disease severity (according to the Total Functional Capacity score, and the UHDRS's Motor score, Behavioural score, and Cognition score), in predicting SF-6D values when respondents first provided data to the REGISTRY study. Standardized beta coefficients were computed to directly compare the strength of prediction of each of the independent variables \[beta coefficients are regression coefficients obtained by first standardising all variables to a mean of 0 and a standard deviation of 1\]. A second regression analysis was conducted as above with the addition of country of residence as 12 binary independent variables, i.e., resident of country X (0) or not resident of country X (1).

Multi-collinearity was assessed by checking correlations between the independent variables, by use of the \_rmdcoll in STATA, prior to inclusion in the regression analysis. The adequacy of the model fit was reviewed by examining a normality plot of residuals and a scatterplot of predicted values versus residual values. All analyses were conducted in Excel and STATA 12, and *p* values of less than 0.05 were considered to be statistically significant.

Results {#Sec14}
=======

Demographic and clinical characteristics {#Sec15}
----------------------------------------

11,328 questionnaires were available from 5560 respondents with HD. Data were provided from more than 12 European countries, including 1510 responses from the UK. The mean (SD) age of respondents was 48.6 (13.3) years and 53% of the sample were female. The mean (SD) time since diagnosis was 4.5 (3.8) years.

Forty-six percent of the respondents were categorised as Stage I in terms of disease progression, 26% Stage II, 21% Stage III, and 7% Stage IV/V. The mean (SD) Total Functional Capacity (TFC) score was 9.04 (3.82), the mean (SD) Behavioural score 12.76 (11.78), the mean (SD) Cognition score 187.49 (85.69), and mean (SD) motor score 29.06 (23.33).

SF-6D health state utility values according to demographic and clinical characteristics {#Sec16}
---------------------------------------------------------------------------------------

Ten thousand nine hundred and twenty-seven unique SF-6D scores were available from respondents from all the countries that the REGISTRY includes, with 10,897 SF-6D HSUVs specific to 12 countries. Unadjusted HSUVs are described below and presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}, Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}.Table 1SF-6D health state utility values by genderMeanStandard deviationMinMaxObservationsIndividualsAll countries Female0.6950540.1449630.3157742836 Male0.7073240.1407010.3151532549Austria Female0.7529550.1376420.3518851 Male0.7835460.1361370.42111058France Female0.6479120.1351840.31795360 Male0.6665120.1385970.31691324Germany Female0.6955950.1493680.311135571 Male0.7010920.1349250.3211026497Italy Female0.6752820.1297830.31248161 Male0.7004930.127460.321223146Netherlands Female0.712350.1413170.31532245 Male0.7049640.1258690.411415182Norway Female0.7262130.1418510.36127273 Male0.7679590.1390010.39124585Poland Female0.6969080.1331930.321705363 Male0.6862350.1349870.31595315Portugal Female0.6895570.1567280.341384136 Male0.7080450.1566220.31266108Spain Female0.7084910.1501030.31636375 Male0.7225170.1531810.321588337Sweden Female0.7450810.1640670.33112452 Male0.7257550.1447140.33113954Switzerland Female0.7222080.133590.3517735 Male0.6996770.125780.430.969337UK Female0.6983620.1424280.31769405 Male0.7265990.1368590.31741390Table 2SF-6D health state utility values by age groupMeanStandard deviationMin.Max.ObservationsIndividualsAll countries Under 35 years0.7603870.1395230.3118111055 35--44 years0.7177710.1450220.3126601451 45--54 years0.6878170.1385920.3128221557 55--64 years0.6749790.1352990.3123261211 65 years and over0.6580510.1360790.311308700Austria Under 35 years0.8110.1023870.6412013 35--44 years0.8092750.1562830.3516934 45--54 years0.7360780.1364270.4215136 55--64 years0.7560610.1026810.5313317 65 years and over0.7160.1132840.510.932516France Under 35 years0.7303510.1488460.36117186 35--44 years0.6703480.134920.31345175 45--54 years0.6415030.1258730.31386205 55--64 years0.6481150.1332380.31382192 65 years and over0.6152970.1328040.341202113Germany Under 35 years0.7743790.1310780.381338203 35--44 years0.7211860.1480780.331531294 45--54 years0.6924750.1357640.31602339 55--64 years0.6598230.1267370.31451239 65 years and over0.6262760.1312030.321239112Italy Under 35 years0.6952730.1373540.3815546 35--44 years0.6995730.1317220.370.9711781 45--54 years0.6698330.1316670.32112084 55--64 years0.6812260.1100280.350.9310672 65 years and over0.698630.1396950.317343Netherlands Under 35 years0.7399270.1277380.39113775 35--44 years0.7317730.1483470.411203104 45--54 years0.7041640.1268140.321269142 55--64 years0.7004370.1287040.411229108 65 years and over0.6586240.1322490.30.9710959Norway Under 35 years0.7668970.1150170.5515826 35--44 years0.7754170.1428990.38112050 45--54 years0.7310180.1563960.36116759 55--64 years0.7249520.1468420.39110343 65 years and over0.7449280.1040310.5116923Poland Under 35 years0.7407010.1453560.31385217 35--44 years0.7000690.1282520.341289165 45--54 years0.662780.1242370.320.96259147 55--64 years0.6589060.1203410.41256138 65 years and over0.6468470.1028770.380.9611167Portugal Under 35 years0.7896080.1435680.42115359 35--44 years0.6913260.1538850.37118173 45--54 years0.6620260.1475430.36115369 55--64 years0.6458330.1335480.3419648 65 years and over0.6552240.1600220.30.966732Spain Under 35 years0.7945080.1302170.331244177 35--44 years0.7460990.1440080.31323208 45--54 years0.6875990.14570.341279180 55--64 years0.6671260.1534730.31247129 65 years and over0.6409920.1329890.38113186Sweden Under 35 years0.7635710.1428340.340.892816 35--44 years0.7622450.1347880.5414922 45--54 years0.7432530.1547230.3318335 55--64 years0.7193850.179460.3316527 65 years and over0.6865790.1282370.4313820Switzerland Under 35 years0.7855170.1197790.5412914 35--44 years0.6918520.1424520.450.932717 45--54 years0.6737780.1160970.430.924525 55--64 years0.6812250.1178740.350.934919 65 years and over0.7760.1220180.540.93208UK Under 35 years0.7566670.1467460.31183114 35--44 years0.7148220.1404590.351394219 45--54 years0.7123570.1382970.321403231 55--64 years0.7026710.1342740.31307177 65 years and over0.6840360.139060.31223120Table 3SF-6D health state utility values by time since diagnosisMeanStandard deviationMin.Max.ObservationsIndividualsAll countries Under 1 year0.6907920.140130.32114011323 1--4 years0.6831080.134820.3137582255 5--9 years0.6590880.133420.3123461388 10 years or more0.6397650.127770.31767449Austria Under 1 year0.7442860.145870.3512828 1--4 years0.7868680.128720.418351 5--9 years0.7464440.126190.4914530 10 years or more0.6536360.112810.490.81110France Under 1 year0.6652580.129560.361194184 1--4 years0.6528030.127390.31610355 5--9 years0.6223190.130190.31401233 10 years or more0.5718090.099880.30.859455Germany Under 1 year0.6840450.140960.321267255 1--4 years0.6769670.128660.321755464 5--9 years0.6594460.131170.31469297 10 years or more0.6493920.140430.31181108Italy Under 1 year0.6831710.127950.3718278 1--4 years0.6968090.125840.321188134 5--9 years0.6520720.124130.350.9711178 10 years or more0.6474070.159340.312718Netherlands Under 1 year0.7013180.132120.321129120 1--4 years0.6918620.126230.31333197 5--9 years0.6679080.113750.361196111 10 years or more0.650.108210.4116036Norway Under 1 year0.7314040.144870.4115753 1--4 years0.7405810.136070.38117279 5--9 years0.7124470.142510.3819440 10 years or more0.7018920.101730.5613713Poland Under 1 year0.684260.1260.381277263 1--4 years0.6642090.125260.321449267 5--9 years0.6495030.116220.380.97201113 10 years or more0.6242860.096760.40.934928Portugal Under 1 year0.6606780.15950.3615953 1--4 years0.6700940.153980.31213114 5--9 years0.6316150.147230.34113070 10 years or more0.6184380.137160.3613216Spain Under 1 year0.6917520.157950.331137130 1--4 years0.6834330.141670.381300210 5--9 years0.6572550.138660.31255147 10 years or more0.6083170.123650.320.8910161Sweden Under 1 year0.6905560.142930.460.931817 1--4 years0.7331110.163350.3419048 5--9 years0.7077780.162370.3318139 10 years or more0.6958330.189230.331127Switzerland Under 1 year0.7640.116730.580.891010 1--4 years0.6982690.14620.350.965227 5--9 years0.6762160.107820.450.853723 10 years or more0.6505260.10250.480.92199UK Under 1 year0.7253150.152760.361143132 1--4 years0.6928540.133050.351508305 5--9 years0.6779010.131280.31324205 10 years or more0.6752780.120620.320.9214488Table 4SF-6D health state utility values by disease stageMeanStandard deviationMinMaxObservationsIndividualsAll countries Stage I0.7668020.1314120.3149912869 Stage II0.6746820.1282710.3127531755 Stage III0.6326160.1207760.3122821500 Stage IV or V0.5745740.1175880.31774571Austria Stage I0.846620.1062340.5717143 Stage II0.7948890.1161630.5214532 Stage III0.6838780.1246970.350.964935 Stage IV or V0.6769570.1374590.4212317France Stage I0.7270540.128180.411577305 Stage II0.6472010.1237650.361393246 Stage III0.595930.1134460.31398264 Stage IV or V0.5441590.1131430.3111393Germany Stage I0.7628880.1325330.381987588 Stage II0.6832870.1265910.31505328 Stage III0.6251950.1157070.320.96435290 Stage IV or V0.5568030.1098250.30.95147116Italy Stage I0.732570.1192090.491214158 Stage II0.6845160.1239020.33112493 Stage III0.6295790.1089110.320.979579 Stage IV or V0.5821620.1340010.30.853732Netherlands Stage I0.7728910.1300580.441422231 Stage II0.6743520.1071850.361239152 Stage III0.6563050.1245210.31203128 Stage IV or V0.6069860.102370.360.967349Norway Stage I0.7886990.1351950.38126999 Stage II0.7163430.1412540.36113466 Stage III0.6952220.12210.380.969043 Stage IV or V0.6265220.1179220.390.882317Poland Stage I0.7583360.1279620.41607367 Stage II0.6518490.1132780.390.97357231 Stage III0.6251650.1026670.30.96273171 Stage IV or V0.564590.0903060.380.766140Portugal Stage I0.7547290.1392550.361387153 Stage II0.6372390.1369180.38113478 Stage III0.5880810.1312010.319961 Stage IV or V0.485790.1232570.340.81915Spain Stage I0.7863460.1330990.31665442 Stage II0.6588410.1266740.331207150 Stage III0.6405560.1192920.30.97198139 Stage IV or V0.5653080.1174550.320.9613077Sweden Stage I0.7888070.1242290.51110956 Stage II0.7305380.1564860.4319340 Stage III0.6678050.1636230.3314130 Stage IV or V0.5868750.1281520.330.771610Switzerland Stage I0.7770240.113730.4518443 Stage II0.6616670.1075040.430.853621 Stage III0.6484380.1186240.350.963221 Stage IV or V0.6017650.0891090.450.761715UK Stage I0.7893530.1234310.391541332 Stage II0.6894790.1309670.351461296 Stage III0.6557180.1210610.31348222 Stage IV or V0.6030480.1207360.30.9610581Fig. 1Mean SF-6D health state utility values by age groupFig. 2Mean SF-6D health state utility values by disease stage

### Gender {#Sec17}

HSUVs are presented in Table [1](#Tab1){ref-type="table"} by gender for the countries as a whole and for each of the 12 countries separately. The general pattern was for women to have lower SF-6D values than men.

### Age {#Sec18}

Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"} present SF-6D values by age group. The data show a decline in values with age. The comparison of SF-6D values by age for people with HD in the UK with values from a representative sample of the UK general population shows SF-6D values of people with HD to be consistently lower than those without the condition in all age groups.

### Time since diagnosis {#Sec19}

Table [3](#Tab3){ref-type="table"} shows a negligible drop in values, as time since diagnosis increases.

### Disease stage {#Sec20}

Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"} indicate that SF-6D values decrease as HD progresses, with the most substantial drop between Stage I and Stage II, both for all the countries combined and the UK separately.

Strength of demographic and clinical characteristics in predicting HSUVs {#Sec21}
------------------------------------------------------------------------

Checks for multi-collinearity indicated that it was appropriate to include all independent variables in the regression model, and examination of normality plots of the regression residuals and scatterplots of predicted SF-6D and residual values also indicated the appropriateness of this analysis (Appendices 1 and 2).

Table [5](#Tab5){ref-type="table"} presents the results of the regression analysis. The model significantly accounted for the variance in SF-6D scores (*n* = 1939; *F* \[7,1931\] = 120.05; *p* \< 0.001; adjusted R-squared 0.3007). TFC score, Behavioural score, and male gender were significant predictors of SF-6D values (all at *p* \< 0.001). The regression results for these variables indicated the following:Table 5Results of random-effects GLS regression to explore relationships between demographic and clinical variables and SF-6D health state utility valuesSF-6D valueCoefficientStandard error*p* \> *z*Lower confidence intervalUpper confidence intervalBeta coefficients^a^TFC score0.00917640.00114860.00000000.00692390.01142900.2328026Behavioural score− 0.00472580.00022880.0000000− 0.0051744− 0.0042771− 0.4053759Cognition score0.00008910.00005960.1350000− 0.00002780.00020600.0430957MOT score− 0.00027560.00020940.1880000− 0.00068620.0001350− 0.0384748Male gender0.01887540.00526310.00000000.00855350.02919730.0686814Age− 0.00029460.00021740.1760000− 0.00072100.0001318− 0.0270106Years since diagnosis0.00145750.00083320.0800000− 0.00017660.00309170.0375215Constant0.65275990.02337940.00000000.60690840.6986114*n *= 1939; *F* \[7,1931\] = 120.05; *p *\< 0.001; Adjusted R-squared 0.3007^a^Beta coefficients were obtained by standardising all variables to a mean of 0 and a standard deviation of 1, and then including them in the regression analysis

(i)The coefficient estimated for the TFC variable was 0.009, indicating that an one point change in the TFC score (range 0--13) corresponded to a 0.009 change in SF-6D score. For example, a decline in independence for a person with HD from a position of functional independence with a TFC score of 13 (Stage I on the TFC scale) to a state of total dependence with a TFC score of 0 (Stage V on the TFC scale) has, on average, a corresponding decrease of 0.119 in their HSUV (i.e., a change of 13 points on the TFC scale equates to a decrease of 0.119 on the SF-6D \[13\*0.0091764\]).(ii)The coefficient for Behavioural score was 0.005, indicating that an increase in behavioural difficulties by one point corresponds to a drop in SF-6D score of 0.005. This equates, for example, to an average drop in SF-6D value of 0.416 from having no behavioural difficulties (score of 0) to having the maximum score on the Behavioural scale (score of 88) \[88\*− 0.0047258\]. Given that a minimally important difference of 0.041 on the SF-6D has been reported \[[@CR22]\], these drops in SF-6D scores in line with increased behavioural difficulties appear to have distinct clinical relevance.(iii)On average, men have SF-6D values 0.019 points higher than women.

The beta weights for the independent variables (given in Table [5](#Tab5){ref-type="table"}) show the relative strength of each of these as predictors of SF-6D values. By far, the strongest predictor was the frequency and severity of behaviour problems (Behavioural score, *β* = − 0.405), followed by the degree of functional independence (TFC score, *β* = 0.233). The next strongest predictor of higher HSUVs was male gender (*β* = 0.069), with the other predictors having relatively negligible effects. The results of the regression analysis including country of residence are shown in Appendix 3.

Discussion {#Sec22}
==========

To our knowledge, this is the first report of HSUVs for HD for countries other than the UK, and the first report of SF-6D values described individually for 12 European countries, broken down by demographic and clinical factors.

Our descriptive analysis indicated that women with HD generally had lower SF-6D HSUVs than men, and this finding held when gender was included in a regression analysis which controlled for other demographic and clinical variables. Although the descriptive data indicated a decline in HSUVs by age group, age was not statistically significantly associated with SF-6D values when other characteristics were controlled for. HSUVs declined by disease stage, with the most substantial drop between Stages I and II. This may be indicative of the fact that some individuals are diagnosed in the pre-manifest stage because of family history of the condition and early predictive testing, and experience no symptoms in Stage I \[[@CR14]\]. This may also explain why there was not a statistically significant relationship between HSUVs and time since diagnosis, as some individuals may be diagnosed with HD and live for decades without any clinical expression, whilst others may only be diagnosed at the point of experiencing significant symptomatology.

The regression analysis indicated a significant association between HSUVs and behavioural symptoms, e.g., sadness/low mood, low self-esteem/guilt, disruptive or aggressive behaviour, obsessions, hallucinations, and irritable behaviour. This relationship was more substantial than the relationship between disease severity (as assessed by functional independence) and HSUVs, suggestive of the key role that such behavioural symptoms may play in HRQoL. Our analyses indicate the importance of these behavioural symptoms in the context of much less significant relationships between cognitive symptoms and HSUVs and motor symptoms and HSUVs, and reflect that although the clinical diagnosis of HD is based on the presence of the movement disorder, behavioural changes appear to be the most debilitating aspect of the condition \[[@CR14]\]. People with HD are eight times more likely to commit suicide than other members of the general population \[[@CR23]\], with HD fracturing lives of entire families: economically, socially, and emotionally. The impacts of HD appear far-reaching with a reported increased prevalence of criminal behaviour in males who carry the gene, and the suggestion that this criminal behaviour is probably linked to the personality changes exhibited as a result of the condition, or related to the depressive reactions to the illness coupled with secondary alcohol misuse \[[@CR24]\].

The size and coverage of the European Huntington's Disease Network REGISTRY study data set has been a major asset for this research. It has enabled us to analyse HSUVs by key demographic variables and clinical factors pertinent to the condition across 12 European countries. Clearly, our results are constrained by the particular measures used in the REGISTRY study. The finding that behavioural symptoms were so strongly related to HSUVs, and cognitive and motor symptoms were not, may be indicative of the instruments used to assess these areas of functioning. However, each of these measures forms part of the United Huntington's Disease Rating Scale (UHDRS) \[[@CR15]\], the main internationally recognised tool for assessing the symptoms of HD.

The ongoing, longitudinal data collection of the REGISTRY study provides a unique opportunity for future research to consider the responsiveness of the SF-6D for people with HD over time, and in relation to treatments that are currently in development. Further research may also usefully explore the comparative responsiveness of the SF-6D and the EQ-5D to health-related changes in the lives of people with HD. The EQ-5D is the most common internationally used preference-based measure for estimating QALYs, and is recommended for use by the UK's National Institute of Health and Care Excellence in health and social care policy decision-making \[[@CR25]\]. It would be of value to determine whether changes in the HRQoL of people with HD are more/less likely to be detected by each of these economic evaluation measures, particularly given that the SF-6D provides higher HSUVs than the EQ-5D because the values are estimated using the standard gamble technique and respondents tend to be risk averse. This is evidenced here as our study found females with HD resident in the UK to have a mean (SD) SF-6D score of 0.698 (0.142), whilst males had a mean (SD) score of 0.727 (0.137). In comparison, the two previous studies that included HSUVs of people with HD, both conducted in the UK, reported EQ-5D scores of a mean (standard deviation) of 0.56 (0.35) \[range − 0.33 to 1\] \[[@CR11]\] and a mean (95% confidence interval) of 0.30 (0.19, 0.41) \[[@CR12]\]. Thus, the SF-6D may demonstrate lower health gains relative to estimates based on the EQ-5D. The development of the international Enroll-HD platform \[[@CR26]\] may provide additional opportunities to address some of these issues.

In conclusion, this research has provided new empirical data on the health state utility values associated with Huntington's disease, in a format that can inform the cost-effectiveness analyses of treatments for people with HD. The provision of this information, based on assessments across a number of European countries, can aid health policy decision makers, clinicians, and people with HD.
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